 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...89101112131415161718...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Disease Characteristics, Treatment and Survival for Oropharyngeal Squamous Cell Carcinoma of Elderly. (Pubmed Central) - Oct 3, 2023
We did not note any significant difference in outcomes among elderly patients treated for OP when compared to the younger patients when multi-disciplinary head and neck cancer care is provided. This was noted even though a significantly larger proportion of elderly patients received cetuximab concurrent with RT as opposed to standard of care cisplatin.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Treatment Tolerance and Toxicity in Elderly Oropharyngeal Cancer Patients and Implication on Outcomes. (Pubmed Central) - Oct 3, 2023
However, survival outcomes are equivalent to younger patients. Ongoing studies should enroll more elderly candidates and stratify endpoints with age.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Impact of Dosimetric Parameters on Local Control and Toxicity of Head and Neck SBRT. (Pubmed Central) - Oct 3, 2023
We appreciated increased use of immunotherapy in our study population from 2019 onwards. We did not find any relationships between dosimetric parameters and rates of grade 3 or higher toxicity, or local control, though our analysis is limited by a small sample size.
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Toxicity and Outcomes of Definitive Local Therapy in Elderly Patients with HPV-Associated Oropharyngeal Cancer. (Pubmed Central) - Oct 3, 2023
Elderly HPV-OPSCC patients treated with definitive intent radiotherapy with or without chemotherapy have favorable disease outcomes with low rates of late toxicity. The Charlson-Comorbidity Index can identify a subset of patients who may have a prolonged OS, and therefore may benefit from more aggressive treatment.
- |||||||||| ficlatuzumab (AV-299) / LG Chem
New P3 trial, Combination therapy, Metastases: FIERCE-HN: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 3, 2023
P3, N=410, Not yet recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920 (Ballroom 20) - Oct 2, 2023 - Abstract #ASTRO2023ASTRO_2619;
Acute but not late toxicity was increased with RT+C. RT+C may be considered for this patient population, but it will be critical to identify subgroups achieving benefit from this combined-modality therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-World Treatment Patterns of Older Adults with Locally Advanced SCCHN Using SEER-Medicare (Hall B2; In Person Only) - Oct 2, 2023 - Abstract #ASTRO2023ASTRO_2602;
We found that a large proportion (42%) of patients did not receive DT regimens in the real-world setting despite known benefits in LA SCCHN. Roughly a quarter of patients required subsequent Tx.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Biomarker, Clinical data, Journal: Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma. (Pubmed Central) - Oct 2, 2023
Of these, only SERPINB5 provided a stronger predictive value than the laminin-encoding genes. Together, these multiple integrated analyses suggest that the combined expression of LM332 is a useful prognostic biomarker for PAAD and could help patient stratification and therapeutic selection.
- | Retrospective data, Journal: Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study. (Pubmed Central) - Oct 1, 2023
This type of information on all the different types of cancer can be useful to better understand the economic burden of the disease and can be decisive for allocating public resources and funds for research, especially in those areas where information is scarce and therefore where further studies are needed. The contribution to knowledge of the cost of oncology therapy is of great value due to its realism and scope.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: SwinCross: Cross-modal Swin transformer for head-and-neck tumor segmentation in PET/CT images. (Pubmed Central) - Sep 30, 2023
Furthermore, the proposed methodology holds applicability to other semantic segmentation tasks involving different imaging modalities like SPECT/CT or PET/MRI. Code:https://github.com/yli192/SwinCross_CrossModalSwinTransformer_for_Medical_Image_Segmentation.
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (MOUNTAINEER-03, trial in progress) (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1429;
P2, P3
Approximately 400 patients will be randomized 1:1 to the TUC experimental arm (TUC [300 mg PO BID] + T + modified FOLFOX) or the SOC arm (modified FOLFOX alone or in combination with either bevacizumab or cetuximab)...Enrollment is ongoing in Europe, with global sites planned. This abstract was previously presented at ESMO 2022, FPN (Final Publication Number): 1037, by Thierry Andre (reused with permission).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study (X1) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1427;
However, compared to literature, synchronous metastases were reported more often in this NIS. Compared to BEACON CRC, BERING CRC pts were older and less pts were documented with ECOG PS 0.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Analysis of efficacy and treatment pattern of second-line therapy after failure of immunotherapy-based treatment in recurrent or metastatic head and neck squamous cell carcinoma (r/m SCCHN) using the head and neck clinical research platform (HEAT) (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_1038;
Cetuximab-based treatment showed higher clinical activity after failure of 1L CPI. Of note, the retrospective nature of our analysis and selection of pts are major limitations.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Sacituzumab-Govitecan (SG) leads to remarkable clinical response in a Trop-2 + HNSCC patient (X2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_670;
Whether SG can contribute to the much-needed improvement in the results of HNSCC treatment and as to whether a putative predictive role of Trop-2 expression can be assumed requires further investigation. This also extends to timing and type of molecular assessment in advanced HNSCC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Blenrep (belantamab mafodotin-blmf) / GSK
Potential Pharmacological Inhibition and Depletion Strategies for CAR-T Cells in Multiple Myeloma (Y2) - Sep 30, 2023 - Abstract #DGHO2023DGHO_550;
ADCC based depletion strategies are highly CAR specific, but rely on a functional NK cell compartment. Similar specificity with diminished NK cell dependency can potentially be reached by the use of ADCs.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR NK cell engagers (Hall D) - Sep 30, 2023 - Abstract #DGHO2023DGHO_47;
Two NKp30-specific VHH, of which one binds a similar epitope on NKp30 as the natural ligand B7-H6, and the other VHH addresses a non-competing epitope were genetically fused in different orientations either to the light chain or heavy chain of a humanized Cetuximab...Especially the targeted epitope on NKp30, the VHH location and the binding valency has a significant impact on effector functions of bispecific NKp30 x EGFR NK cell engagers. These findings reveal novel insights for the engineering of potent NKCEs triggering the NKp30 axis.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
A Car-Engineered Primary Nk Cells Show Promising Effects As Targeted Therapy Against Egfr-Positive Glioblastoma (Grote Zaal Foyer) - Sep 28, 2023 - Abstract #EANO2023EANO_287;
In summary, these results demonstrate promising efficacy of primary CAR-NK cells targeting EGFR and EGFRvIII both in vitro and in vivo. In ongoing work we are evaluating CAR-pNK cells in an orthotopic LNT-229 glioblastoma xenograft mouse model, which may provide the basis to translate this approach to early clinical testing.
- Akalux (cetuximab sarotalocan) / Rakuten Medical
Development of a novel, cellular-level drug uptake quantification pipeline for accurate estimation of fluorescence-conjugated therapeutics: data from the phase 1b/2 open-label study ASP-1929 (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1602;
P1/2
Methods We have developed a cellular-level drug quantification pipeline based on multiplex immunofluorescence imaging to measure the amount of ASP-1929 (cetuximab-IR700) that reaches the tumor site and binds the epidermal growth factor receptor (EGFR). Using this method, we show good tumor penetration and target binding of ASP-1929 in patients with HNSCC enrolled in ASP-1929
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1575;
Conclusions The developed model can adequately describe the effects of Cetuximab observed in in vitro experiments. The model was applied to estimate contribution of ADCC and direct effect of Cetuximab at various E:T ratios and EGFR expression levels.
- A three stage immune targeted immuno-cytokine platform that delivers inflammatory signals to the tumor microenvironment (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1373;
Co-fusion of cis-acting IL-15 and IL-18 combines their beneficial properties, including expansion, persistence, and memory. This innovative approach to targeted and combined cytokine delivery holds great promise as a new and disruptive treatment paradigm for cancer.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Single cell analysis of neutrophil heterogeneity reveals anti-tumoral phenotypes and its implications for immune-checkpoint blockade therapy in head and neck cancer (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1287;
, 2023) by injecting MOC2-huEGFR, a syngeneic mouse HNSCC cancer line expressing humanized EGFR, into the flanks of WT C57BL/6 mice with recombinant TNF-alpha, anti-CD40 agonist, and anti-EGFR (Cetuximab)...Conclusions We showed that distinct pro and anti-tumoral neutrophil subsets exist in the HNSCC murine models, and our preliminary data indicated that modulating neutrophils toward anti-tumoral phenotypes could promote an ICB-responsive TME. Ongoing and future work include identifying the mechanism by which anti-tumoral neutrophils are induced and if these multifaceted phenotypes could be recapitulated with patient samples.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tecentriq (atezolizumab) / Roche
A quantitative systems pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1200;
Conclusions The developed QSP model can adequately describe the effects of various drug therapies, including chemotherapy and immunotherapies, and their combinations on progression and outcomes of head and neck cancers. The model can be used as a tool for evaluating treatment outcomes for standard and novel therapies.
- nanrilkefusp alfa (SOT101) / Sotio
Nanrilkefusp alfa, a high-affinity IL-15R?? agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1046;
P1, P2
Conclusions Nanrilkefusp alfa boosts both the innate and adaptive immune system and induces proinflammatory changes in the microenvironment of multiple tumor types as single-agent and in combination with pembrolizumab. An extended evaluation of nanrilkefusp alfa in combination with pembrolizumab or cetuximab is currently ongoing in phase 2 clinical trials in patients with selected advanced solid tumors (NCT05256381, NCT05619172).
- Loqtorzi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Updated safety and efficacy of toripalimab combined with cetuximab in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC): a phase Ib/II clinical trial (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1012;
P1/2
No fatal AEs related to the study treatment was reported. Conclusions Toripalimab combined with cetuximab were well tolerated and showed promising clinical efficacy in patients with R/M HNSCC.
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC) (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1007;
Analysis will use a 1-sided log-rank test at a significance level= 0. 025 and the uniformly most powerful conditionally unbiased criterion to control the Type 1 error.
- Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Increased efficacy of cetuximab after pembrolizumab failure in cutaneous squamous cell carcinoma (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_905;
8 This present study is especially unique as it adds three cases to the underreported body evidence on treating advanced cSCC with cetuximab after immunotherapy. Additionally, whereas prior studies primarily used Nivolumab, in the present study Pembrolizumab was the primary immunotherapy agent.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Understanding cetuximab response and immune modulation in colorectal cancer using patient-derived organotypic tumor spheroids (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_427;
Additionally, whereas prior studies primarily used Nivolumab, in the present study Pembrolizumab was the primary immunotherapy agent. Our findings align with clinical observations, demonstrating the platform
- BCA101 / Biocon
Combination with BCA101 improves the efficacy of KRAS-G12C inhibitor and overcomes G12C inhibitor-induced resistance in lung and colon cancer cell lines (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_376;
This resistance is rescued by a combination of the G12Ci with BCA101 but not cetuximab...Conclusions Preclinical results show that BCA101 has the potential to increase the efficacy of G12Ci along with the ability to mitigate G12Ci-induced acquired resistance in lung and colon cancer cell lines. This study provides a rationale to combine BCA101 with G12Ci in G12C mutant lung or colon cancer patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, FDG PET: Adaptive FDG-PET/CT guided dose escalation in head and neck squamous cell carcinoma: Late toxicity and oncologic outcomes (The ADMIRE study). (Pubmed Central) - Sep 27, 2023
P=N/A
Cisplatin or cetuximab was added to radiotherapy in case of T3-4 and/or N2c disease. The adjusted OR for any late G3 toxicity was 5.09 (95
- | metformin / Generic mfg.
Journal: Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients. (Pubmed Central) - Sep 25, 2023
In conclusion, real-world outcomes of biweekly cetuximab maintenance remain comparable to clinical trials. The prognostic role of diabetes and metformin was confirmed to be significant in our series, but further prospective studies are needed for a definitive evaluation.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, P3 data, Clinical Trial,Phase III, Journal: Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. (Pubmed Central) - Sep 25, 2023
This novel molecular classification warrants further study as a possible predictive biomarker for personalized systemic treatment for colorectal liver metastases. isrctn.org Identifier: ISRCTN22944367.
- | pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
Trial completion date: KEYNOTE-B75: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) (clinicaltrials.gov) - Sep 25, 2023
P2, N=120, Active, not recruiting, Sponsor: Sanofi
isrctn.org Identifier: ISRCTN22944367. Trial completion date: Feb 2024 --> Aug 2024
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: CD98 expression can be a predictive factor of resistance to radiotherapy in head and neck squamous cell carcinoma. (Pubmed Central) - Sep 24, 2023
Via CD98 immunostaining, sensitivity to radiotherapy can be determined in advance. In HNSCC, knowledge about sensitivity to radiotherapy can significantly improve prognosis.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal, Metastases: Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Sep 22, 2023
P2
A more complete assessment of MAPK pathway mutations warrants further investigation to the refine treatment strategy for patients with RAS wild-type mCRC. ClinicalTrials.gov Identifier: NCT02404935.
- QTX3034 / Quanta Therap
QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity (Level 2, Exhibit Hall D) - Sep 22, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_711;
- ||| FT536 / Fate Therap
Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Monotherapy, Metastases: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (clinicaltrials.gov) - Sep 21, 2023
P1, N=5, Terminated, Sponsor: Fate Therapeutics
ClinicalTrials.gov Identifier: NCT02404935. Trial completion date: Apr 2027 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Aug 2023; This study was terminated by the Sponsor.
- ||| FT538 / Fate Therap
Trial completion date, Trial termination, Combination therapy, Metastases: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (clinicaltrials.gov) - Sep 21, 2023
P1, N=16, Terminated, Sponsor: Fate Therapeutics
Trial completion date: Apr 2027 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Aug 2023; This study was terminated by the Sponsor. Trial completion date: Aug 2025 --> Aug 2023 | Active, not recruiting --> Terminated; This study was terminated by the Sponsor.
- ||| BND-22 / Biond Biologics, Sanofi
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Sep 21, 2023
P1/2, N=456, Recruiting, Sponsor: Sanofi
Trial completion date: Aug 2025 --> Aug 2023 | Active, not recruiting --> Terminated; This study was terminated by the Sponsor. N=130 --> 456 | Trial completion date: Jan 2024 --> May 2027 | Trial primary completion date: Sep 2023 --> May 2027
- |||| Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, magrolimab (ONO-7913) / Ono Pharma
New P2 trial, Metastases: Phase II Trial of Magrolimab and Cetuximab with Pembrolizumab or Docetaxel for Recurrent/metastatic Head Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 21, 2023
P2, N=57, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC. (Pubmed Central) - Sep 20, 2023
In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy.
- Clinical Utility of Next Generation Sequencing in Advanced Colorectal Cancer: The Earlier The Better. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_344;
- BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in KRAS G12V-driven preclinical models. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_242;
- | CB-NK-TGF-βR2-/NR3C1 / UT MD Anderson Cancer Center
Trial completion date, Trial primary completion date, Combination therapy, Minimal residual disease: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) (clinicaltrials.gov) - Sep 14, 2023
P1, N=15, Recruiting, Sponsor: M.D. Anderson Cancer Center
These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy. Trial completion date: Jun 2023 --> Feb 2027 | Trial primary completion date: Jun 2023 --> Feb 2027
- || Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, evorpacept (ALX148) / ALX Oncology
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov) - Sep 14, 2023
P2, N=80, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Jun 2023 --> Feb 2027 | Trial primary completion date: Jun 2023 --> Feb 2027 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2023 --> Sep 2024
- | Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023. (Pubmed Central) - Sep 14, 2023
For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy...Patients should be engaged in informed, shared decision-making on management and be provided with the
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona "variable". (Pubmed Central) - Sep 14, 2023
In this work, we explore and compare the two edge cases of EVs modified with the antibody Cetuximab (CTX) by chemisorption of CTX (through covalent binding via biorthogonal click-chemistry) and by formation of a physisorbed CTX corona. The results indicate that (i) no differences exist between the two formulations in terms of binding affinity imparted by molecular recognition of CTX versus its natural binding partner (epidermal growth factor receptor, EGFR), but (ii) significant differences emerge at the cellular level, where CTX-EVs prepared by click chemistry display superior binding and uptake toward target cells, very likely due to the higher robustness of the CTX anchorage.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, Metastases: Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC). (Pubmed Central) - Sep 14, 2023
More recently, the combination of anti-EGFR therapy with immunotherapy has been shown activity with complementary mechanisms. Hence, anti-EGFR therapy in combination with immunotherapy may hold the key to improving the therapeutic effect of refractory mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, New P2 trial, Combination therapy, Metastases: Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancer (EUDRACT) - Sep 13, 2023
P2, N=29, Not yet recruiting, Sponsor: Australasian Gastrointestinal Trials Group
- || FDA event, Review, Journal, PARP Biomarker: Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. (Pubmed Central) - Sep 13, 2023
FDA-approved drugs like osimertinib and crizotinib specifically inhibit these aberrant pathways, providing remarkable benefits in patients with EGFR-mutated or ALK-positive lung cancer...Bevacizumab and cetuximab are prominent FDA-approved agents that hinder VEGF and EGFR signaling, significantly enhancing outcomes in metastatic colorectal cancer patients...Drugs like enzalutamide, apalutamide, and darolutamide effectively inhibit AR signaling, demonstrating efficacy in castration-resistant prostate cancer. This review further highlights promising targets like mesenchymal-epithelial transition (MET), ROS1, BRAF, and poly(ADP-ribose) polymeras (PARP) in specific cancer subsets, along with ongoing clinical trials that continue to shape the future of targeted therapy.
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: AVETRIC: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Sep 13, 2023
P2, N=58, Active, not recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
This review further highlights promising targets like mesenchymal-epithelial transition (MET), ROS1, BRAF, and poly(ADP-ribose) polymeras (PARP) in specific cancer subsets, along with ongoing clinical trials that continue to shape the future of targeted therapy. Trial completion date: Dec 2023 --> Jul 2024